AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM

EP: 1.Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM

EP: 2.Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations

Now Viewing

EP: 3.AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM

EP: 4.Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024

EP: 5.Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials

EP: 6.Strategic Use of Bispecific Antibodies in R/R MM

EP: 7.Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM

EP: 8.Integrating Bispecific Antibodies Into Clinical Practice

EP: 9.Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025

EP: 10.Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Video content above is prompted by the following:

• How are you evolving your approach to maintenance therapy in newly diagnosed multiple myeloma (NDMM)? What factors do you consider, and how do you balance potential survival benefits with tolerability? Please highlight the latest data from the AURIGAtrial, evaluating Dara+Len maintenance in NDMM.
• AURIGA trial, subgroup analysis